Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Set To Exercise 1-For-10 Reverse Stock Split


Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) recently announced that it would be exercising a 1-for-10 reverse stock split, of all outstanding shares of the company’s common stock. Moreover, RNN would also exercise a corresponding proportional reduction in the number of authorized capital shares of the company, as well. The action is expected to be executed on May 5, 2017, with the stock starting to trade on the NYSEMKT, on a split-adjusted basis.

The company expects that its shareholders would receive cash in lieu of any fraction of shares, formed as a result of the split. The CEO of Rexahn, Peter D. Suzdak, stated that the board feels that this is an appropriate time for implementing a reverse split. He also thanked the shareholders for their continued support and patience. Mr. Suzdak further claimed that the move is likely to make their stock more attractive to the financial community, particularly institutional investors. He also stated that this support has helped them advance clinical development of targeted therapies, for cancer patients.

Currently, Rexhan is working on several drug candidates, aimed at several different types of cancers. The company’s RX-3117 is a clinical development candidate, for the treatment of pancreatic cancer, which is currently in the phase-2a of clinical trials. Similarly, RNN has Supinoxin and Archexin, are in the phase-2a clinical trials as well. The drugs are developed as treatments for triple negative breast cancer and renal cell carcinoma, respectively.

Earlier, the company announced its financial results for the 4Q2016, recording a net loss of $16.4 million. This was lower than the loss from the preceding year, while Rexahn’s cash position declined by approximately $3 million. As such, RNN’s cash position stood at $20.3 million, by the end of the 4Q2016. It is expected that this amount is sufficient to fund the company’s activities, through the 1Q2018.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at a share price of $0.427, after having a trade volume of 1.48 million, during the May 1 trading session, 0.33% higher than the session before.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.